Etrasimod is a novel sphingosine-1-phosphate receptor modulator, first approved for marketing by the U.S. Food and Drug Administration (FDA) in 2023. As an oral medication for the treatment of moderately to severely active ulcerative colitis, etrasimod provides a new therapeutic option for patients with this chronic inflammatory bowel disease.
Indications of Etrasimod
Main Therapeutic Area
Clinical studies have confirmed that etrasimod is specifically indicated for the treatment of moderately to severely active ulcerative colitis in adults.
Ulcerative colitis is a chronic, non-specific inflammatory bowel disease that primarily affects the colonic mucosa and submucosa. Its clinical manifestations include symptoms such as diarrhea, mucopurulent bloody stools, and abdominal pain.
Etrasimod exerts its effects by regulating the immune system, which can effectively control disease activity and improve patients’ symptoms.
Characteristics of Eligible Populations
This medication is indicated for adult patient populations and has demonstrated efficacy in patients with moderate to severe active disease in clinical trials.
It is important to note that etrasimod is not indicated for patients with mild ulcerative colitis, nor is it suitable for pediatric patient populations.
Specifications and Characteristics of Etrasimod
Dosage Form and Specifications
The currently marketed dosage form of etrasimod is oral film-coated tablets, with each tablet containing 2mg of etrasimod as the active ingredient.
This specification is the recommended therapeutic dose determined based on clinical trial results, which balances therapeutic efficacy and safety.
Description of Physical Characteristics
Appearance and Form: Round tablets.
Color Characteristic: Green film coating.
Imprint Information: One side is embossed with the letters "ETR", and the other side is embossed with the number "2", facilitating identification and dose differentiation.
Storage Methods of Etrasimod
Routine Storage Conditions
Temperature Control: Should be stored at room temperature between 20°C and 25°C.
Humidity Management: Maintain a dry environment and protect from moisture.
Light Protection: Store away from light, preferably keeping the medication in its original packaging until use.
Special Precautions
The medication should be kept out of the reach of children.
Do not store the medication in high-humidity areas such as bathrooms or kitchens.
Regularly inspect the appearance of the medication; if abnormal discoloration or changes in characteristics are found, discontinue use.
Pay attention to the expiration date of the medication; expired medications should be disposed of promptly.
